BellRing Brands (BRBR)
(Delayed Data from NYSE)
$63.19 USD
+0.44 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.18 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.19 USD
+0.44 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.18 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
Zacks News
Is BellRing Brands (BRBR) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Introduces New Drug Coated Balloon Catheter
by Zacks Equity Research
Medtronic's (MDT) newly-launched Prevail DCB demonstrates impressive safety and drug deliverability, utilizing a rapid absorption drug to treat patients with coronary artery disease.
Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.
NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery
by Zacks Equity Research
The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.
Medtronic's (MDT) Hugo RAS System Now Available at UC CHRISTUS
by Zacks Equity Research
Recent integration of Medtronic's (MDT) Hugo RAS System at UC CHRISTUS is intended to support the teaching institution's new robotic surgery program.
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Thermo Fisher (TMO) Advances Customer Research With New Launch
by Zacks Equity Research
Thermo Fisher's (TMO) new instrument enables high-resolution images of nanoparticles and beam-sensitive materials to be obtained from a commercially available desktop SEM.
Thermo Fisher (TMO) to Meet Plasmid DNA Demand With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility will manufacture materials that are essential for production of plasmid-based therapies and vaccines.
Is BellRing Brands (BRBR) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Integra's (IART) SurgiMend Gets Innovative Technology Contract
by Zacks Equity Research
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices
by Zacks Equity Research
Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on robust international growth and raised 2021 outlook.
Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval
by Zacks Equity Research
Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.
Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal
by Zacks Equity Research
With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
by Zacks Equity Research
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
by Zacks Equity Research
Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
by Zacks Equity Research
Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.
IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).
Here's Why You Should Add STERIS (STE) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.
QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt
by Zacks Equity Research
With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.
NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA, Lumentum, Maravai LifeSciences, Baxter International and BellRing Brands highlighted as Zacks Bull and Bear of the Day
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
by Riya Anand
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.